MarketResearchReports.com: Non-Small Cell Lung Cancer - Pipeline Review, H2 2013, New Report Launched

Non-Small Cell Lung Cancer - Pipeline Review, H2 2013 report provides an overview of the indication’s therapeutic pipeline. This report also reviews key players involved in the therapeutic development for Non-Small Cell Lung Cancer. Non-Small Cell Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from publisher  proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by publisher team. 

Scope

• A snapshot of the global therapeutic scenario for Non-Small Cell Lung Cancer.
• A review of the Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Coverage of products based on various stages of development ranging from discovery till registration stages.
• A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
• Coverage of the Non-Small Cell Lung Cancer pipeline on the basis of route of administration and molecule type.
• Key discontinued pipeline projects.
• Latest news and deals relating to the products.

Reasons to buy

• Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Cancer.
• Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
• Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
• Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Spanning over 447 pages, 234 tables and 14 figures, “Non-Small Cell Lung Cancer - Pipeline Review, H2 2013”  report provides information on the therapeutic development for Non-Small Cell Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

In addition to covering the Non-Small Cell Lung Cancer Overview, Non-Small Cell Lung Cancer Therapeutics under Development by Companies, Non-Small Cell Lung Cancer Therapeutics under Investigation by Universities/Institutes, Late Stage Products, Mid Clinical Stage Products, Early Clinical Stage Products, Discovery and Pre-Clinical Stage Products, Companies Involved in Non-Small Cell Lung Cancer Therapeutics Development, Non-Small Cell Lung Cancer Therapeutics - Drug Profile Updates, Non-Small Cell Lung Cancer Therapeutics - Discontinued Products, Non-Small Cell Lung Cancer Therapeutics - Dormant Products, Non-Small Cell Lung Cancer - Product Development Milestones.  The report covers 138 companies; few are Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Biogen Idec Inc., Shionogi & Co., Ltd., Amgen Inc., Sanofi-Aventis, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Genentech, Inc., Nektar Therapeutics, Inovio Biomedical Corporation, MedImmune LLC.

Find all: Pharma and Healthcare Market Research Reports